Melatonin agonist treatment
AssigneeVanda Pharmaceuticals Inc.
InventorsGunther Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Melatonin Agonist, MA-1, is administered at effective doses.
Claims8
A method for forward shifting melatonin onset in a human subject experiencing a 5 hour circadian phase advance, said method comprising orally administering to the subject 20 mg/d (1R-trans)-N-r-(2,3-dihydro-4-benzofuranyl)cyclopropyllmethyllpropanamide (MA-1) in immediate release form at or within 2 hours prior to the subject's phase-advanced bedtime.
A method of treating a circadian rhythm disorder associated with a 5-hour circadian phase advance in a human subject, said method comprising forward shifting the circadian sleep-wake cycle in the subject by orally administering to the subject 20 mg/d (1R-trans)-N-r-(2,3-dihydro-4-benzofuranyl)cyclopropyllmethyll propanamide (MA-1) in immediate release form at or within 2 hours prior to the subject's phase-advanced bedtime.
Dependencies are inferred from the claim text.